Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Behavioral and Brain Functions
Published in: Behavioral and Brain Functions 1/2017

Open Access 01-12-2017 | Short paper

Drug-induced Parkinson’s disease modulates protein kinase A and Olfactory Marker Protein in the mouse olfactory bulb

Authors: Carla Mucignat, Antonio Caretta

Published in: Behavioral and Brain Functions | Issue 1/2017

Login to get access

Abstract

Background

Olfaction is often affected in parkinsonian patients, but dopaminergic cells in the olfactory bulb are not affected by some Parkinson-inducing drugs. We investigated whether the drug MPTP produces the olfactory deficits typical of Parkinson and affects the olfactory bulb in mice.

Findings

Lesioned and control mice were tested for olfactory search, for motor and exploratory behavior. Brains and olfactory mucosa were investigated via immunohistochemistry for thyrosine hydroxylase, Olfactory Marker Protein and cyclic AMP-dependent protein kinase as an intracellular pathway involved in dopaminergic neurotransmission. MPTP induced motor impairment, but no deficit in olfactory search. Thyrosine hydroxylase did not differ in olfactory bulb, while a strong decrease was detected in substantia nigra and tegmentum of MPTP mice. Olfactory Marker Protein decreased in the olfactory bulb of MPTP mice, while a cyclic AMP-dependent protein kinase increased in the inner granular layer of MPTP mice.

Conclusions

MPTP mice do not present behavioural deficits in olfactory search, yet immunoreactivity reveals modifications in the olfactory bulb, and suggests changes in intracellular signal processing, possibly linked to neuron survival after MPTP.
Literature
1.
2.
Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res. 2004;318:121–34.CrossRefPubMed
3.
Del Tredici K, Rub U, De Vos RA, Bohl JR, Braak H. Where does Parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol. 2002;61:413–26.CrossRefPubMed
4.
Pearce RK, Hawkes CH, Daniel SE. The anterior olfactory nucleus in Parkinson’s disease. Mov Disord. 1995;10:283–7.CrossRefPubMed
5.
Daniel SE, Hawkes CH. Preliminary diagnosis of Parkinson’s disease by olfactory bulb pathology. Lancet. 1992;340:186.CrossRefPubMed
6.
Koster NL, Norman AB, Richtand NM, Nickell WT, Puche AC, Pixley SK, Shipley MT. Olfactory receptor neurons express D2 dopamine receptors. J Comp Neurol. 1999;411:666–73.CrossRefPubMed
7.
Gutierrez-Mecinas M, Crespo C, Blasco-Ibanez JM, Gracia-Llanes FJ, Marques-Mari AI, Nacher J, Varea E, Martinez-Guijarro FJ. Distribution of D2 dopamine receptor in the olfactory glomeruli of the rat olfactory bulb. Eur J Neurosci. 2005;22:1357–67.CrossRefPubMed
8.
Mania-Farnell BL, Farbman AI, Bruch RC. Bromocriptine, a dopamine D2 receptor agonist, inhibits adenylyl cyclase activity in rat olfactory epithelium. Neuroscience. 1993;57:173–80.CrossRefPubMed
9.
Bruenig I, Sommer M, Hatt H, Borkmann J. Dopamine receptor subtypes modulate olfactory bulb gamma-aminobutyric acid type A receptors. Proc Natl Acad Sci USA. 1999;96:2456–60.CrossRef
10.
Liu Z, Zhang J, Fei J, Guo L. A novel mechanism of dopamine neurotoxicity involving the peripheral extracellular and the plasma membrane dopamine transporter. NeuroReport. 2001;29:3293–7.CrossRef
11.
Riederer F, Luborzewski A, God R, Bringmann G, Scholz J, Feineis D, Moser A. Modification of tyrosine hydroxylase activity by chloral derived β-carbolines in vitro. J Neurochem. 2002;81:814–9.CrossRefPubMed
12.
Oh JD, Del Dotto P, Chase TN. Protein kinase A inhibitor attenuates levodopa-induced motor response alterations in the hemi-parkinsonian rat. Neurosci Lett. 1997;228:5–8.CrossRefPubMed
13.
Fieblinger T, Sebastianutto I, Alcacer C, Fieblinger T, Sebastianutto I, Alcacer C, Bimpisidis Z, Maslava N, Sandberg S, Engblom D, Cenci MA, et al. Mechanisms of dopamine D1 receptor-mediated ERK1/2 activation in the parkinsonian striatum and their modulation by metabotropic glutamate receptor type 5. J Neurosci. 2014;34:4728–40.CrossRefPubMed
14.
Kawahata I, Ohtaku S, Tomioka Y, Ichinose H, Yamakuni T. Dopamine or biopterin deficiency potentiates phosphorylation at (40)Ser and ubiquitination of tyrosine hydroxylase to be degraded by the ubiquitin proteasome system. Biochem Biophys Res Commun. 2015;465:53–8.CrossRefPubMed
15.
Muda K, Bertinetti D, Gesellchen F, Hermann JS, von Zweydorf F, Geerlof A, Jacob A, Ueffing M, Gloeckner CJ, Herberg FW. Parkinson-related LRRK2 mutation R1441C/G/H impairs PKA phosphorylation of LRRK2 and disrupts its interaction with 14-3-3. Proc Natl Acad Sci USA. 2014;111:E34–43.CrossRefPubMed
16.
Qureshi HY, Paudel HK. Parkinsonian neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and alpha-synuclein mutations promote Tau protein phosphorylation at Ser262 and destabilize microtubule cytoskeleton in vitro. J Biol Chem. 2011;286:5055–68.CrossRefPubMed
17.
18.
Curtis MA, Faull RL, Eriksson PS. The effect of neurodegenerative diseases on the subventricular zone. Nat Rev Neurosci. 2007;8:712–23.CrossRefPubMed
19.
Hoeglinger GU, Rizk P, Muriel MP, Duyckaerts C, Oertel WH, Caille I, Hirsch EC. Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat Neurosci. 2004;7:726–35.CrossRef
20.
Giachino C, De Marchis S, Giampietro C, Parlato R, Perroteau I, Schuetz G, Fasolo A, Peretto P. cAMP response element-binding protein regulates differentiation and survival of newborn neurons in the olfactory bulb. J Neurosci. 2005;25:10105–18.CrossRefPubMed
21.
Mucignat-Caretta C, Bondi’ M, Caretta A. Animal models of depression: olfactory lesions affect amygdala, subventricular zone, and aggression. Neurobiol Dis. 2004;16:386–95.CrossRefPubMed
22.
Sedelis M, Schwarting RKW, Huston JP. Behavioral phenotyping of the MPTP mouse model of Parkinson’s disease. Behav Brain Res. 2001;125:109–22.CrossRefPubMed
23.
Mucignat-Caretta C, Caretta A. Regional variations in the localization of insoluble kinase A regulatory isoforms during rodent brain development. J Chem Neuroanat. 2004;27:201–12.CrossRefPubMed
24.
Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24:197–211.CrossRefPubMed
25.
Asakawa T, Fang H, Sugiyama K, Nozaki T, Hong Z, Yang Y, Hua F, Ding G, Chao D, Fenoy AJ, Villarreal SJ, Onoe H, Suzuki K, Mori N, Namba H, Xia Y. Animal behavioral assessments in current research of Parkinson’s disease. Neurosci Biobehav Rev. 2016;65:63–94.CrossRefPubMed
26.
27.
Kurosaki R, Muramatsu Y, Kato H, Araki T. Biochemical, behavioral and immunohistochemical alterations in MPTP-treated mouse model of Parkinson’s disease. Pharmacol Biochem Behav. 2004;78:143–53.CrossRefPubMed
28.
Doty RL, Singh A, Tetrud J, Langston JW. Lack of major olfactory dysfunction in MPTP-induced parkinsonism. Ann Neurol. 1992;32:97–100.CrossRefPubMed
29.
Kurtenbach S, Wewering S, Hatt H, Neuhaus EM, Lübbert H. Olfaction in three genetic and two MPTP-induced Parkinson’s disease mouse models. PLoS ONE. 2013;8(10):e77509.CrossRefPubMedPubMedCentral
30.
Brown RG, Jahanshahi M. Cognitive-motor dysfunction in Parkinson’s disease. Eur Neurol. 1996;36:24–31.CrossRefPubMed
31.
32.
Fleming SM, Tetreault NA, Mulligan CK, Hutson CB, Masliah E, Chesselet MF. Olfactory deficits in mice overexpressing human wildtype α-synuclein. Eur J Neurosci. 2008;28:247–56.CrossRefPubMedPubMedCentral
33.
Xu Z, Cawthon D, McCastlain KA, Slikker W Jr, Ali SF. Selective alterations of gene expression in mice induced by MPTP. Synapse. 2005;55:45–51.CrossRefPubMed
34.
Tinti C, Conti B, Cubells JF, Kim KS, Baker H, Joh TH. Inducible cAMP Early Repressor can modulate tyrosine hydroxylase gene expression after stimulation of cAMP synthesis. J Biol Chem. 1996;271:25375–81.CrossRefPubMed
35.
Cash R, Raisman R, Ploska A, Agid Y. Dopamine D-1 receptor and cyclic AMP-dependent phosphorylation in Parkinson’s disease. J Neurochem. 1987;49:1075–83.CrossRefPubMed
36.
Andoh T, Chock PB, Murphy DL, Chiueh CC. Role of the redox protein thioredoxin in cytoprotective mechanism evoked by (–)-deprenyl. Mol Pharmacol. 2005;68:1408–14.CrossRefPubMed
37.
Hulley P, Hartikka J, Abdel’Al S, Engels P, Buerki HR, Wiederhold KH, Muller T, Kelly P, Lowe D, Lubbert H. Inhibitors of type IV phosphodiesterases reduce the toxicity of MPTP in substantia nigra neurons in vivo. Eur J Neurosci. 1995;7:2431–40.CrossRefPubMed
38.
Young EA, Duchemin AM, Neff NH, Hadjiconstantinou M. Parallel modulation of striatal dopamine synthetic enzymes by second messenger pathways. Eur J Pharmacol. 1998;357:15–23.CrossRefPubMed
39.
Betarbet R, Poisik O, Sherer TB, Greenamyre JT. Differential expression and Ser 897 phosphorylation of striatal N-methyl-d-aspartate receptor subunit NR1 in animal models of Parkinson’s disease. Exp Neurol. 2004;187:76–85.CrossRefPubMed
40.
Yamada M, Onodera M, Mizuno Y, Mochizuki H. Neurogenesis in olfactory bulb identified by retroviral labeling in normal and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated adult mice. Neuroscience. 2004;124:173–81.CrossRefPubMed
41.
Winner B, Geyer M, Couillard-Despres S, Aigner R, Bogdahn U, Aigner L, Kuhn G, Winkler J. Striatal deafferentiation increases dopaminergic neurogenesis in the adult olfactory bulb. Exp Neurol. 2006;197:113–21.CrossRefPubMed
42.
Mitsumoto Y, Mori A, Ohashi S, Nakai M, Moriizumi T. Differential effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the olfactory bulb and the striatum in mice. Neurosci Res. 2005;51:111–5.CrossRefPubMed
Metadata
Title
Drug-induced Parkinson’s disease modulates protein kinase A and Olfactory Marker Protein in the mouse olfactory bulb
Authors
Carla Mucignat
Antonio Caretta
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Behavioral and Brain Functions / Issue 1/2017
Electronic ISSN: 1744-9081
DOI
https://doi.org/10.1186/s12993-017-0119-2

Other articles of this Issue 1/2017

Behavioral and Brain Functions 1/2017 Go to the issue

Research

Brain structural investigation and hippocampal tractography in medication overuse headache: a native space analysis

Research

Cognitive behavioural therapy attenuates the enhanced early facial stimuli processing in social anxiety disorders: an ERP investigation

Research

Effects of GABAB receptors in the insula on recognition memory observed with intellicage

Research

Logical fallacies in animal model research

Short report

Behavioral sensitivity of Japanese children with and without ADHD to changing reinforcer availability: an experimental study using signal detection methodology

Research

Neurobehavioral changes in mice offspring exposed to green tea during fetal and early postnatal development